Phenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure?

Circ Heart Fail. 2023 Jan;16(1):e010222. doi: 10.1161/CIRCHEARTFAILURE.122.010222. Epub 2022 Dec 16.

Ayodeji Awoyemi¹, Johannes R Hov^{2

3

4}, Marius Trøseid^{3

5

4}

¹ Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Norway (A.A.).
² Norwegian PSC Research Center and Section of Gastroenterology, Department of Transplantation Medicine (J.R.H.), Oslo University Hospital, Norway.
³ Research Institute of Internal Medicine (J.R.H., M.T.), Oslo University Hospital, Norway.
⁴ Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway (J.R.H., M.T.).
⁵ Section for Clinical Immunology and Infectious Diseases (M.T.), Oslo University Hospital, Norway.

No abstract available

Keywords: Editorials; cardiovascular disease; heart failure; phenylacetylglutamine; prognosis.

Publication types